Saunders, Rebecca
Ramesh, Jayapal
Cicconi, Silvia
Evans, Jonathan
Yip, Vincent S.
Raraty, Michael
Ghaneh, Paula
Sutton, Robert
Neoptolemos, John P.
Halloran, Christopher
Article History
Received: 18 December 2017
Accepted: 31 August 2018
First Online: 6 September 2018
Compliance with ethical standards
:
: Prof. Neoptolemos discloses personal fees from AMGEN and Mylan; grants from Taiho Pharma (Japan), KAEL GemVax (Korea), AstraZeneca, Clovis Oncology and Ventana, Pharma Nord and NUCANA; personal fees from Boehringer Ingelheim Pharma GmbH & Co. KG, Novartis Pharma AG, KAEL GemVax, and Astellas. Prof. Sutton discloses grants from Cypralis Research, GlaxoSmithKline, Innovate UK (with Cypralis Ltd) and Merck/MSD: Supply of drug for trial (other aspects of trial funded by UK MRC and NIHR). Dr Ramesh is a Consultant for Boston Scientific. Miss Saunders, Miss Cicconi, Dr Evans, Mr Yip, Mr Raraty, Prof Ghaneh and Mr Halloran have no conflicts of interest or financial ties to disclose.